Browse SLC26A1

Summary
SymbolSLC26A1
Namesolute carrier family 26 (anion exchanger), member 1
Aliases SAT-1; solute carrier family 26 (sulfate transporter), member 1; sulfate anion tranporter AT1; sulfate/anion ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein Basolateral cell membrane
Domain PF01740 STAS domain
PF00916 Sulfate permease family
Function

Mediates sulfate transport with high affinity (PubMed:12713736). Mediates oxalate transport (PubMed:12713736). Mediates bicarbonate transport (By similarity). Does not accept succinate as cosubstrate (By similarity).

> Gene Ontology
 
Biological Process GO:0006164 purine nucleotide biosynthetic process
GO:0006790 sulfur compound metabolic process
GO:0006820 anion transport
GO:0006821 chloride transport
GO:0006835 dicarboxylic acid transport
GO:0006885 regulation of pH
GO:0008272 sulfate transport
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009163 nucleoside biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0015698 inorganic anion transport
GO:0015701 bicarbonate transport
GO:0015711 organic anion transport
GO:0019532 oxalate transport
GO:0030004 cellular monovalent inorganic cation homeostasis
GO:0030641 regulation of cellular pH
GO:0033865 nucleoside bisphosphate metabolic process
GO:0033866 nucleoside bisphosphate biosynthetic process
GO:0033875 ribonucleoside bisphosphate metabolic process
GO:0034030 ribonucleoside bisphosphate biosynthetic process
GO:0034032 purine nucleoside bisphosphate metabolic process
GO:0034033 purine nucleoside bisphosphate biosynthetic process
GO:0034035 purine ribonucleoside bisphosphate metabolic process
GO:0034036 purine ribonucleoside bisphosphate biosynthetic process
GO:0042278 purine nucleoside metabolic process
GO:0042391 regulation of membrane potential
GO:0042451 purine nucleoside biosynthetic process
GO:0042455 ribonucleoside biosynthetic process
GO:0044272 sulfur compound biosynthetic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046129 purine ribonucleoside biosynthetic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046942 carboxylic acid transport
GO:0050427 3'-phosphoadenosine 5'-phosphosulfate metabolic process
GO:0050428 3'-phosphoadenosine 5'-phosphosulfate biosynthetic process
GO:0051453 regulation of intracellular pH
GO:0055067 monovalent inorganic cation homeostasis
GO:0072348 sulfur compound transport
GO:0072522 purine-containing compound biosynthetic process
GO:0098656 anion transmembrane transport
GO:0098661 inorganic anion transmembrane transport
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901657 glycosyl compound metabolic process
GO:1901659 glycosyl compound biosynthetic process
GO:1902358 sulfate transmembrane transport
GO:1902476 chloride transmembrane transport
Molecular Function GO:0005216 ion channel activity
GO:0005253 anion channel activity
GO:0005254 chloride channel activity
GO:0008271 secondary active sulfate transmembrane transporter activity
GO:0008509 anion transmembrane transporter activity
GO:0008514 organic anion transmembrane transporter activity
GO:0015103 inorganic anion transmembrane transporter activity
GO:0015106 bicarbonate transmembrane transporter activity
GO:0015108 chloride transmembrane transporter activity
GO:0015116 sulfate transmembrane transporter activity
GO:0015267 channel activity
GO:0015291 secondary active transmembrane transporter activity
GO:0015297 antiporter activity
GO:0015301 anion:anion antiporter activity
GO:0019531 oxalate transmembrane transporter activity
GO:0022803 passive transmembrane transporter activity
GO:0022804 active transmembrane transporter activity
GO:0022838 substrate-specific channel activity
GO:0099516 ion antiporter activity
GO:1901682 sulfur compound transmembrane transporter activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-211859: Biological oxidations
R-HSA-156584: Cytosolic sulfonation of small molecules
R-HSA-1630316: Glycosaminoglycan metabolism
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-427601: Multifunctional anion exchangers
R-HSA-156580: Phase II conjugation
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-174362: Transport and synthesis of PAPS
R-HSA-425393: Transport of inorganic cations/anions and amino acids/oligopeptides
Summary
SymbolSLC26A1
Namesolute carrier family 26 (anion exchanger), member 1
Aliases SAT-1; solute carrier family 26 (sulfate transporter), member 1; sulfate anion tranporter AT1; sulfate/anion ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SLC26A1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSLC26A1
Namesolute carrier family 26 (anion exchanger), member 1
Aliases SAT-1; solute carrier family 26 (sulfate transporter), member 1; sulfate anion tranporter AT1; sulfate/anion ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SLC26A1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSLC26A1
Namesolute carrier family 26 (anion exchanger), member 1
Aliases SAT-1; solute carrier family 26 (sulfate transporter), member 1; sulfate anion tranporter AT1; sulfate/anion ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SLC26A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.170.445
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5390.196
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0980.786
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.1080.0154
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.160.622
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0460.734
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0950.815
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0510.936
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2270.744
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1890.787
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3980.664
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0510.803
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SLC26A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.35.98.40.576
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1032033.3-13.31
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSLC26A1
Namesolute carrier family 26 (anion exchanger), member 1
Aliases SAT-1; solute carrier family 26 (sulfate transporter), member 1; sulfate anion tranporter AT1; sulfate/anion ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC26A1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSLC26A1
Namesolute carrier family 26 (anion exchanger), member 1
Aliases SAT-1; solute carrier family 26 (sulfate transporter), member 1; sulfate anion tranporter AT1; sulfate/anion ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC26A1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC26A1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSLC26A1
Namesolute carrier family 26 (anion exchanger), member 1
Aliases SAT-1; solute carrier family 26 (sulfate transporter), member 1; sulfate anion tranporter AT1; sulfate/anion ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC26A1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSLC26A1
Namesolute carrier family 26 (anion exchanger), member 1
Aliases SAT-1; solute carrier family 26 (sulfate transporter), member 1; sulfate anion tranporter AT1; sulfate/anion ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SLC26A1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSLC26A1
Namesolute carrier family 26 (anion exchanger), member 1
Aliases SAT-1; solute carrier family 26 (sulfate transporter), member 1; sulfate anion tranporter AT1; sulfate/anion ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SLC26A1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSLC26A1
Namesolute carrier family 26 (anion exchanger), member 1
Aliases SAT-1; solute carrier family 26 (sulfate transporter), member 1; sulfate anion tranporter AT1; sulfate/anion ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SLC26A1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.